# Tactile Systems Technology, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Tactile Systems Technology, Inc). ## Overview Tactile Systems Technology is a U.S.-based medical technology company that develops and sells home-based devices for chronic disease management. Its core offerings address lymphedema, chronic venous insufficiency, and airway clearance therapy, with sales concentrated in the United States through a direct-to-patient and provider model. ## Products & services • Flexitouch Plus home therapy systems • Entre Plus lymphedema treatment systems • Nimbl compression systems • AffloVest airway clearance therapy • Patient support, billing, and reimbursement services - **Lymphedema therapy systems** (78%) — Home-use pneumatic compression devices for lymphedema and related venous disease. - **Airway clearance therapy** (22%) — Vest-based respiratory therapy devices used to help clear mucus in chronic lung conditions. - Flexitouch Plus home therapy systems - Entre Plus lymphedema treatment systems - Nimbl compression systems - AffloVest airway clearance therapy - Patient support, billing, and reimbursement services ## Customers The company sells primarily to patients in the United States, with reimbursement and access shaped by physicians, payers, and durable medical equipment channels. Its products are used by people with chronic conditions such as lymphedema, chronic venous insufficiency, and respiratory disease, often after clinical referral and payer approval. - **Lymphedema patients** (primary) — Buy Flexitouch Plus, Entre Plus, and Nimbl systems for home treatment of swelling and related symptoms. - **Chronic venous insufficiency patients** (secondary) — Use compression therapy devices to manage venous disease and related edema. - **Respiratory patients** (secondary) — Buy AffloVest systems for airway clearance in chronic respiratory conditions. - **Healthcare providers and payers** (primary) — Influence product adoption through referrals, coverage decisions, and reimbursement pathways. - Patients with lymphedema seeking at-home compression therapy - Cancer survivors with secondary lymphedema needs - Patients with chronic venous insufficiency - Patients with chronic respiratory conditions needing airway clearance - Physicians, clinics, and payers that influence prescribing and coverage ## Geography The business is concentrated in the United States, which is both its main sales market and operating base. The company also maintains trademark registrations in several non-U.S. markets, but the disclosed revenue base is overwhelmingly U.S.-centric. - United States is the core sales and operating market - Direct sales force and reimbursement operations are U.S.-based - Minneapolis metropolitan area houses major corporate/manufacturing functions - Trademark registrations extend to Australia, Japan, EU, New Zealand, and UK - Geographic concentration increases dependence on U.S. payer and regulatory rules ## Strategy The company’s strategy centers on expanding home-based treatment adoption for underserved chronic diseases through direct clinical and patient engagement. It emphasizes sales-force productivity, payer access, clinical evidence, and product expansion to strengthen its position in the U.S. home-therapy market. - **Expand direct commercial reach** (short-term) — A direct model helps the company control patient education, access, and conversion. - **Strengthen reimbursement and payer access** (short-term) — Coverage criteria and billing privileges are central to device adoption and revenue realization. - **Grow the product portfolio** (medium-term) — New devices broaden the addressable market and reduce reliance on a single product line. - Expand direct sales coverage to reach more patients and providers - Increase payer awareness and reimbursement support for home therapy - Broaden the product portfolio across lymphedema and respiratory care - Use clinical evidence to support adoption and coverage decisions - Improve productivity in a direct-to-patient and -provider model ## Risks The company depends heavily on Medicare coverage, payer criteria, and durable medical equipment accreditation, so reimbursement changes could materially affect demand and access. It also faces intense competition, technology change, and operational risks tied to direct sales, manufacturing, cybersecurity, and product performance. - **Medicare coverage and reimbursement changes** [high] — A large share of patients rely on Medicare, so coverage criteria directly affect utilization and collections. - **Competitive pressure in pneumatic compression and airway clearance** [high] — Rivals with broader resources or distribution can pressure pricing, share, and customer acquisition. - **Accreditation and licensing compliance** [high] — The direct-to-patient model depends on maintaining DME certification and related approvals. - **Cybersecurity and IT disruption** [medium] — Patient, billing, and operational systems are exposed to intrusion, outage, or data breach risk. - **Product performance and recall risk** [medium] — Device defects can affect patient safety, trigger field actions, and damage reputation. - Medicare coverage or criteria changes could reduce patient access - Competition may intensify as rivals improve products and distribution - Direct model requires accreditation and licensing compliance - Cybersecurity or system failures could disrupt operations and trust - Product functionality issues could trigger recalls or patient safety events ## Accounting Revenue recognition is a key accounting area because the company sells and rents devices and estimates expected consideration using payer and patient collection history. Seasonality also affects comparability across quarters, while estimates around collectability, rebates, and reimbursement can move reported revenue and margins. The company has also disclosed fair value accounting for an earn-out related to AffloVest, showing that valuation judgments can affect earnings when contingent liabilities are remeasured. - **Revenue recognition and collectability estimates** — Can change reported revenue if payer or patient collections differ from estimates - **Seasonality** — Affects revenue and expense comparability across periods - **Contingent consideration / earn-out fair value** — Can create non-cash gains or losses in the income statement - Revenue recognition depends on transfer of control and expected consideration - Collectability estimates use payer and patient payment history - Sales and rentals create timing differences in reported revenue - Seasonality can make quarterly results uneven - Fair value remeasurement of contingent earn-outs can affect earnings --- *Last updated: 2026-04-29T05:01:14.522908+00:00*